A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding

BACKGROUND: Andexanet alfa (andexanet) and prothrombin complex concentrate (PCC) are both reversal agents for major bleeding in patients using factor Xa inhibitors (FXaIs). Our aim was to evaluate the current evidence for the effectiveness and safety of andexanet and PCC in a systematic review and m...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaspers, Tessa, Shudofsky, Kimberly, Huisman, Menno V., Meijer, Karina, Khorsand, Nakisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143276/
https://www.ncbi.nlm.nih.gov/pubmed/34084991
http://dx.doi.org/10.1002/rth2.12518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143276/
https://www.ncbi.nlm.nih.gov/pubmed/34084991
http://dx.doi.org/10.1002/rth2.12518

Ejemplares similares